XML 35 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity
12 Months Ended
Oct. 31, 2020
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
11
Stockholders' Equity
Stock Repurchase Program
On December 3, 2015, the company's Board authorized the repurchase of 8,000,000 shares of the company's common stock in open-market or in privately negotiated transactions. On December 4, 2018, the company's Board authorized the repurchase of up to an additional 5,000,000 shares of common stock in open-market or in privately negotiated transactions under the authorized stock repurchase program. This authorized stock repurchase program has no expiration date but may be terminated by the Board at any time.
No shares were repurchased under the authorized stock repurchase program during fiscal 2020. The company curtailed the repurchase of shares of its common stock during fiscal 2020 as a result of the Venture Products transaction and to enhance its liquidity position in response to COVID-19. During fiscal 2019 and 2018, the company paid $20.0 million and $160.4 million to repurchase an aggregate of 359,758 shares and 2,579,864 shares, respectively, under the authorized stock repurchase program. As a result of the CMW transaction, the company curtailed the repurchase of shares of its common stock under the authorized stock repurchase program during the company's fiscal 2019 second, third, and fourth quarters. As of October 31, 2020, 7,042,256 shares remained authorized by the company's Board for repurchase. The authorized stock repurchase program does not include shares of the company's common stock surrendered by employees to satisfy minimum tax withholding obligations upon vesting of certain stock-based compensation awards granted under the company's 2010 plan.
Treasury Shares
Treasury shares generally consist of shares of the company's common stock repurchased under the company's Board authorized stock repurchase program. The company values treasury shares on an average cost basis. As of October 31, 2020, the company had a total of 20,545,330 treasury shares at an average cost of $1,323.2 million. As of October 31, 2019, the company had a total of 21,385,919 treasury shares at an average cost of $1,374.0 million.
Accumulated Other Comprehensive Loss
The components of AOCL, net of tax, within the Consolidated Statements of Stockholders' Equity were as follows (in thousands):
As of October 31202020192018
Foreign currency translation adjustments$24,508 $31,025 $29,711 
Pension and post-retirement benefits5,106 4,861 561 
Cash flow derivative instruments4,648 (3,837)(6,335)
Total accumulated other comprehensive loss$34,262 $32,049 $23,937 
The components and activity of AOCL, net of tax, were as follows (in thousands):
 Foreign Currency Translation AdjustmentsPension BenefitsCash Flow Derivative InstrumentsTotal
Balance as of October 31, 2019$31,025 $4,861 $(3,837)$32,049 
Other comprehensive (income) loss before reclassifications(6,517)245 14,159 7,887 
Amounts reclassified from AOCL— — (5,674)(5,674)
Net current period other comprehensive (income) loss(6,517)245 8,485 2,213 
Balance as of October 31, 2020$24,508 $5,106 $4,648 $34,262 
 Foreign Currency Translation AdjustmentsPension and Post-Retirement BenefitsCash Flow Derivative InstrumentsTotal
Balance as of October 31, 2018$29,711 $561 $(6,335)$23,937 
Other comprehensive (income) loss before reclassifications1,314 4,300 (4,048)1,566 
Amounts reclassified from AOCL— — 6,546 6,546 
Net current period other comprehensive loss1,314 4,300 2,498 8,112 
Balance as of October 31, 2019$31,025 $4,861 $(3,837)$32,049 
For additional information on the components reclassified from AOCL to the respective line items in net earnings for derivative instruments refer to Note 14, Derivative Instruments and Hedging Activities.